Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial
Akira Sezai(Nihon University), Atsushi Hirayama(Nihon University), Kazutomo Minami(Nihon University), Toshiko Nakai(Nihon University), Isamu Yoshitake(Nihon University), Mitsumasa Hata(Nihon University), Motomi Shiono(Nihon University), Shinji Wakui(Nihon University)
Cited by 96
Related Papers
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
|Circulation|2018|242
Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients (NU-FLASH Trial)
|Circulation Journal|2013|120
Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)
|ESC Heart Failure|2020|109
Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting
|Journal of the American College of Cardiology|2011|108